Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857350 · ClinicalTrials.gov registry record
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 60
- Enrollment target
NCT00857350: Completed study, sponsored by Yale University.
NCT00857350 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00857350 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-09 |
What the finished NCT00857350 record still lists
NCT00857350 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00857350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00857350 about?
NCT00857350 is a clinical study titled "The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment". HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. ...
What is the current status of trial NCT00857350?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2008-06. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT00857350?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia